Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.
Naqvi S, He H, Siddiqi R, Khan N, Khakwani K, Ayaz A, Singh P, Ho T, Bryce A, McGregor B, Xu W, Bin Riaz I. Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis. Journal Of Clinical Oncology 2023, 41: 695-695. DOI: 10.1200/jco.2023.41.6_suppl.695.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMixed treatment comparisonGraphical user interfaceTreatment comparisonsRule-based algorithmSystematic reviewUser interfaceSignificant PFS benefitAdditional survival benefitFirst-line treatmentCertainty of evidenceEfficacious treatment optionRenal cell carcinomaBayesian networkSignificant differencesQuality of lifeAutomated fashionRisk of toxicityEvidence synthesis frameworkImmunotherapy combinationsMRCC patientsOS benefitPFS benefitSynthesis frameworkTreatment toxicity